Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis.

Li M, Yang Y, Jiang D, Ying M, Wang Y, Zhao R.

Medicine (Baltimore). 2017 Sep;96(39):e8161. doi: 10.1097/MD.0000000000008161. Review.

2.

Metformin combined with acarbose vs. single medicine in the treatment of type 2 diabetes: A meta-analysis.

Liu Z, Zhao X, Sun W, Wang Y, Liu S, Kang L.

Exp Ther Med. 2017 Jun;13(6):3137-3145. doi: 10.3892/etm.2017.4333. Epub 2017 Apr 13.

3.
4.

A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs.

Ankarfeldt MZ, Adalsteinsson E, Groenwold RH, Ali MS, Klungel OH.

Clin Epidemiol. 2017 Jan 23;9:41-51. doi: 10.2147/CLEP.S121991. eCollection 2017. Review.

5.

Effectiveness and Safety of Sitagliptin in Patients with Beta-thalassaemia Major and Diabetes Mellitus: A Case Series.

Zonoozi S, Barnard M, Prescott E, Jones R, Shah FT, Tzoulis P.

Mediterr J Hematol Infect Dis. 2017 Jan 1;9(1):e2017004. doi: 10.4084/MJHID.2017.004. eCollection 2017.

6.

Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.

Liu X, Men P, Wang Y, Zhai S, Liu G.

Lipids Health Dis. 2016 Nov 23;15(1):204.

7.

The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial.

Rahimi HR, Mohammadpour AH, Dastani M, Jaafari MR, Abnous K, Ghayour Mobarhan M, Kazemi Oskuee R.

Avicenna J Phytomed. 2016 Sep-Oct;6(5):567-577.

8.

Update on the treatment of type 2 diabetes mellitus.

Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Del Cañizo-Gómez FJ.

World J Diabetes. 2016 Sep 15;7(17):354-95. doi: 10.4239/wjd.v7.i17.354. Review.

9.

Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.

Park SH, Nam JY, Han E, Lee YH, Lee BW, Kim BS, Cha BS, Kim CS, Kang ES.

Medicine (Baltimore). 2016 Aug;95(32):e4543. doi: 10.1097/MD.0000000000004543.

10.

A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.

Patel CA, Bailey RA, Vijapurkar U, Meininger G, Blonde L.

BMC Health Serv Res. 2016 Aug 5;16(a):356. doi: 10.1186/s12913-016-1607-z.

12.

Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy.

Hayes J, Anderson R, Stephens JW.

Drug Des Devel Ther. 2016 Jul 19;10:2263-70. doi: 10.2147/DDDT.S93076. eCollection 2016. Review.

13.

Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis.

Andersen SE, Christensen M.

Br J Clin Pharmacol. 2016 Nov;82(5):1291-1302. doi: 10.1111/bcp.13059. Epub 2016 Aug 3. Review.

PMID:
27426428
14.

Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.

Kim JY, Yang S, Lee JI, Chang MJ.

PLoS One. 2016 Apr 14;11(4):e0153502. doi: 10.1371/journal.pone.0153502. eCollection 2016. Review.

15.

The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials.

Varvaki Rados D, Catani Pinto L, Reck Remonti L, Bauermann Leitão C, Gross JL.

PLoS Med. 2016 Apr 12;13(4):e1001992. doi: 10.1371/journal.pmed.1001992. eCollection 2016 Apr. Review. Erratum in: PLoS Med. 2016 Jun;13(6):e1002091.

16.

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.

Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, Zhang L, Shen J, Bala MM, Sohani ZN, Wong E, Busse JW, Ebrahim S, Malaga G, Rios LP, Wang Y, Chen Q, Guyatt GH, Sun X.

BMJ. 2016 Feb 17;352:i610. doi: 10.1136/bmj.i610. Review.

17.

Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis.

Chen C, Yu Q, Zhang S, Yang P, Wang CY.

Int J Clin Exp Pathol. 2015 Nov 1;8(11):14141-50. eCollection 2015. Review.

18.

Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus.

Kumar S, Pathak AK, Saikia D, Kumar A.

J Clin Diagn Res. 2015 Dec;9(12):FC07-10. doi: 10.7860/JCDR/2015/17027.6888. Epub 2015 Dec 1.

19.

Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study.

Takeshita Y, Takamura T, Kita Y, Takazakura A, Kato K, Isobe Y, Kaneko S.

BMJ Open Diabetes Res Care. 2015 Aug 28;3(1):e000122. doi: 10.1136/bmjdrc-2015-000122. eCollection 2015.

20.

Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes.

Goswami G, Shinkazh N, Davis N.

J Clin Med. 2014 Jun 18;3(2):595-613. doi: 10.3390/jcm3020595. Review.

Supplemental Content

Support Center